Metabolic interventions including special diets and supplements are commonly used in Autism Spectrum Disorder (ASD). Yet little is known about how these interventions, typically initiated by caregivers, may affect metabolic function or the core symptoms of ASD. This review examines possible direct and indirect roles for metabolism in the core symptoms of ASD as well as evidence for metabolic dysfunction and nutritional deficiencies. We also discuss some of the most popular diets and supplements used in our patient population and suggest strategies for discussing the utility of these interventions with patients, families, and caregivers.
Autism Spectrum Disorder (ASD) affects 1 in 59 children in the U.S. and is characterized by childhood-onset, lifelong difficulties with social interaction, communication and sensory perception (Baio et al., 2018; Brugha et al., 2016) . ASD is a heterogenous group of disorders. Severity can range from individuals who are non-verbal with little awareness, or interest, in the social world to high-functioning individuals who excel in many cognitive domains but have difficulty understanding social interactions and communication. Current diagnosis is based on clinical criteria (see the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, DSM-5) and may incorporate neuropsychological testing using common standardized scales such as the Autism Diagnostic Observation Scale (ADOS; Lord et al., 2012) . Genetic testing is increasingly common as hundreds of genes have been associated with ASD (Sanders, 2018) . ASD is highly heritable (60-95%; Colvert et al., 2015) , and currently genetic causes can be identified in up to 40% of cases (Choueiri and Zimmerman, 2017; Wiśniowiecka-Kowalnik and Nowakowska, 2019) . Treatments are limited primarily to symptomatic management of medical and psychiatric comorbidities including seizures, anxiety, attentional deficits, sleep disturbances, and gastrointestinal issues (Neumeyer et al., 2018a) . A variety of medications (onand off-label) are used to try to reduce repetitive or harmful behaviors-either self-injurious or aggression toward others-with mixed success. Although there are clinical trials in progress testing novel therapies to improve social interaction (Choueiri and Zimmerman, 2017) , there are currently no approved medications for treating the core symptoms of ASD, nor are there any that affect the disorder's progression. Behavioral therapies, including applied behavior analysis (Dawson, 2008) , are the most evidence-based interventions available for targeting core features of ASD and related behavioral symptoms. This educational support for language and social development is most effective when started as early in development as possible.
Metabolic contributions to behavior in ASD

Mechanisms of cognitive dysfunction in ASD
There is growing evidence that widespread, mild synaptic dysfunction may underlie the core symptoms of ASD (Ebrahimi-Fakhari and Sahin, 2015; Johnson et al., 2015; Meredith et al., 2012) . Multiple genetic mutations identified in ASD are in synaptic proteins, and animal models of genetic forms of ASD show multiple deficits in both excitatory and inhibitory synaptic function (Bourgeron, 2009; Mierau et al., 2016) . Synaptic dysfunction leads to altered sensory processing during early postnatal development, which can already be detected within the first months of life (Blasi et al., 2015; Jones and Klin, 2013) . Early differences in visual and auditory processing can also been seen in higher-level functions including attention, in particular to socially relevant stimuli (Braukmann et al., 2018; Lloyd-Fox et al., 2017) . These studies in infants provide evidence for an altered trajectory of sensory and cognitive development in ASD, with social and language difficulties manifesting as the common core symptoms due to their demands on sensory processing and reinforcement learning during early postnatal development . This raises an important distinction when observing autistic behaviors: which symptoms arise directly atypical response to the environment based on an altered trajectory of development?
Primary metabolic disorders with features of ASD
This distinction is particularly important when considering the role metabolism may play in altered cognition in ASD. Genetic mutations affecting metabolic function in neurons, for example in the mitochondria, may directly lead to the synaptic dysfunction in a subpopulation of people with ASD (Cheng et al., 2017) . In these cases, one might postulate that correcting or modulating mitochondrial function, if technically possible, might improve synaptic function and potentially enhance the individual's ability to learn and adapt to his or her environment. There is also evidence that some children with undiagnosed metabolic disorders, perhaps missed in newborn screening that varies by region, can be mistakenly diagnosed with ASD. Investigators identified inborn errors of metabolism in 5 out of 187 children previously diagnosed with ASD in Crete (Spilioti et al., 2013) , including one case of phenylketonuria (PKU). This likely represents less than 1% of the ASD population, however, as the incidence of metabolic disorders in a French cohort identified only 2 people with potential metabolic disorders out of 274 people with ASD-similar to the risk of metabolic disorders in the general population. The rest of the cohort had metabolic parameters in the normal range (Schiff et al., 2011) .
Others have noted the overlap of symptoms in known metabolic disorders and ASD. Frye (2015) reviewed six categories of metabolic disorders that may show phenotypic overlap with ASD including: disorders of energy, cholesterol, cofactor (e.g., vitamin deficiencies), gabaergic, pyrimidine and purine, and amino acid metabolism. This overlap may explain the anecdotal cases of dramatic resolution of ASD when an individual is treated with a specific metabolic replacement therapy (Adams et al., 2018) . However, caution should be made in drawing conclusions that widespread metabolic dysfunction produces the specific symptoms that bind ASD as a diagnosis. Most of these metabolic disorders exhibit a global developmental delay-a specific exclusion for a diagnosis of ASD-along with a significant number of phenotypic features unrelated to ASD (Frye, 2015) that would suggest specific syndromes and point away from ASD as a diagnosis. Thus, when considering studies linking ASD with a high prevalence of comorbid metabolic disorders, it is important to examine the stringency with which the diagnosis of ASD was applied.
Secondary contributions of metabolism to ASD
Metabolic dysfunction may also play a secondary role in ASD. One of the major challenges for people with ASD who are nonverbal or have limited communication is expressing discomfort. Thus, physical pain, frustration, and irritability can all manifest as either self-injurious or aggressive behaviors. This difficulty with communication can mask other underlying medical conditions, particularly gastrointestinal distress, which is common in ASD (Buie et al., 2010) . Many people with ASD also have restricted food interests which may alter the microbiome of the gut (Buie, 2015; Mulle et al., 2013) This can lead to gastrointestinal symptoms directly, as the microbiome affects the breakdown of many foods to absorbable metabolites and competes with pathogenic bacteria (Heintz-Buschart and Wilmes, 2018) . However, the microbiome may also contribute to systemic metabolic dysfunction in ASD through (1) different bacterial metabolites absorbed into the bloodstream affecting downstream cellular processes in the body and the brain, (2) decreased synthesis of essential vitamins by the microbiome, and (3) effects on the immune system (Buie, 2015; Heintz-Buschart and Wilmes, 2018; Mulle et al., 2013) . In all of these instances, identifying and treating metabolic dysfunction would be expected to improve behavioral outcomes in affected individuals. There is also the potential for targeting metabolism to modulate cognitive function in people with ASD, as there is a large body of literature connecting healthy eating, for example, with improved cognitive function in neurotypical persons across the lifespan (Buie, 2015) .
Possible wider role for metabolism in the pathogenesis of ASD
Metabolism includes the biochemical processes for converting food into energy to power cells and into building blocks for synthesizing cellular components as well as eliminating waste (López-Otín et al., 2016) . It begins with digestion and absorption of nutrients and other metabolites into the bloodstream and continues with processes at the cellular and organ level (López-Otín et al., 2016; Shaffer et al., 2017) . Disruption at any of these stages could contribute to primary and/or secondary contributions to ASD (Cheng et al., 2017; Frye, 2015; Schiff et al., 2011) . Given the heterogeneity in people diagnosed with ASD, one might predict a small sub-population in which metabolic disturbances at the cellular level, particularly in pathways necessary for neuronal function, may be the primary cause of the widespread synaptic dysfunction underlying the altered developmental trajectory in cognitive development. One such candidate is mitochondrial dysfunction (Cheng et al., 2017) . Risk genes for mitochondrial dysfunction have been identified in people with ASD, including SLC25AI2, TMLHE, IMMP2L, and multiple monogenic animal models of ASD, including Mecp2, Ube3a, TSC, Foxg1, show evidence of mitochondrial dysfunction (Cheng et al., 2017) . While less than 5% of people with ASD fulfill the criteria for classic mitochondrial diseases, there is speculation more people with ASD could have underlying mitochondrial dysfunction Frye, 2014, 2012) . This is partly based on blood tests showing a higher incidence of metabolic abnormalities in people with ASD; however, many of these studies are quite small and not controlled for diet or medication use (Frye, 2015; West et al., 2014) . Moreover, it is unclear whether these metabolic changes may contribute to the etiology of ASD, or whether they are a consequence of the disorder in which restricted diets are common and well documented. Metabolomic studies in blood plasma are affected in a dynamic fashion by the gut microbiome, which can change rapidly with dietary changes (Shaffer et al., 2017) . Mixed results have also been seen in many attempts to correct metabolic defects ). Yet, even in cases where improvement in autistic (or gastrointestinal) symptoms were seen, it is unclear whether these interventions indicated a direct role for metabolic dysfunction or were correcting secondary nutritional deficiencies caused by the core features of ASD. Further research is underway to explore these connections, although it is yet unclear, particularly in the animal models, to what degree the mitochondrial dysfunction contributes to ASD pathophysiology.
Nutrition in ASD
The effect of diet and the downstream metabolic consequences can have a profound effect on behavior and quality of life in people with ASD who have no known metabolic disorder. First, restricted diets are common in our patient population and are often due to sensory sensitivities to the texture, taste, smell, or color of the food. A meta-analysis including 881 children with ASD found that children with ASD are five times more likely to have feeding issues than children without ASD . Second, people with severe forms of ASD may require additional nutritional supplementation in order to avoid vitamin deficiencies; however, this can also be challenging since the majority of these individuals have difficulty swallowing pills (Beck et al., 2005; Ghuman et al., 2004) . Thus, in our clinical experience, many caregivers often resort to hiding supplements in favorite sugary drinks or snacks. Third, nutrition can also be further restricted in ASD by families or caregivers who have chosen special diets with the hope of improving the core symptoms of ASD . Fourth, gastrointestinal (GI) problems are common in people with ASD, in particular gastroesophageal reflux disease (GERD) and constipation (Buie et al., 2010; McElhanon et al., 2014) . GI distress is often missed in people with ASD who have limited verbal abilities because discomfort from multiple causes may all be expressed as self-injurious, repetitive, or aggressive behaviors (Buie et al., 2010) . Changes in diet and nutrition may temporarily exacerbate or relief symptoms. Aggressive treatment of GERD and constipation can dramatically reduce harmful behaviors and lead to improved nutrition as the GI system heals (Buie et al., 2010) . Finally, mood, concentration, energy, and ease of social interaction are all affected by dietary intake in people with and without ASD. While a person without ASD may be irritable and have difficulty concentrating after skipping a meal, for example, a person with ASD who is nonverbal may be affected in a similar way but express their frustration and fatigue through self-injurious or aggressive behaviors. An example from our clinic is a non-verbal teenage boy whose parents had him on a healthy, gluten-free diet with very limited carbohydrates. After being treated to a new snack product-gluten-free potato chips-for the first time, he was so excited he went to the kitchen that night, after everyone else was asleep, and ate the entire package of gluten-free potato chips. This unusual addition to his typically healthy diet gave him the additional energy to stay awake much of the night. During the next two days he exhibited, for the first time, physical aggression at school causing considerable concern to his family and other caregivers (as the connection to the diet and sleep disturbance was not immediately made). His behavior returned to normal within a few days consistent with recovery from a night of sleep deprivation.
Correcting nutritional deficiencies in ASD
Food intolerances and nutritional deficiencies may go undiagnosed in people ASD, particularly those with limited communication (Buie et al., 2010) . Many studies aimed at replacing nutritional deficiencies have shown promise for improving autistic symptoms and quality of life, especially in people with ASD with previously undiagnosed vitamin deficiencies or food intolerances (Ranjan and Nasser, 2015) . For example, a 12-month, single-blinded study of a comprehensive approach to nutrition (combining vitamin/mineral supplements, fatty acids, carnitine, digestive enzymes and a gluten-free, casein-free, soy-free diet) in small cohort of children and adults with ASD showed modest absolute improvements in autistic symptoms, with a high degree of variability among participants (Adams et al., 2018) . Of note, this study was done to test the efficacy of a similar nutritional regimen that this center was already advocating. Due to the large number of nutritional changes incorporated into the treatment strategy, it is difficult to pinpoint which single components, if any, would justify a general recommendation to persons with ASD. Moreover, multiple meta-analyses of the individual components of nutritional replacements strategies have shown inconclusive results. Studies show dramatic or no benefits with varying degrees of bias in study design .
Interestingly, several of the case studies revealed previously unrecognized nutritional deficiencies or food intolerances (e.g., carnitine deficiency in a child who avoided meats and a man with lactose intolerance), which resulted dramatic clinical recovery of specific symptoms in those individuals (Adams et al., 2018) . This highlights potential advantages for individual patients in evaluating the likelihood of deficiencies based on the individual's current nutritional state and specific symptoms needing treatment. A generalizable approach for the primary care physician would be to review the dietary intake of patients with ASD-possibly with the help of a nutritionist, if there are concerns-to pinpoint the most likely nutritional deficiencies (Buie et al., 2010) . Notably, the most common deficiencies in ASD (e.g., calcium, vitamin D) are also the most prevalent in the general pediatrics population (Hyman et al., 2012) . Once identified, attempts to correct nutritional deficiencies can be made one at a time, based on the order of likelihood, and evaluated, keeping in mind the expected timeframe for improvement (which could be days to months depending on the intervention). The same can be done for eliminating foods. Here family history can be particularly informative, especially when the person with ASD is unable to answer specific symptom-related question (e.g., do you have cramping after eating or drinking dairy products?). Another key rationale for taking a more serial approach is the difficulty and expense for the caregivers in following specialized regimens. Compliance in studies ranges from 60 to 90% depending on the difficulty of the administration with exclusion of certain foods or components of food being the most challenging .
Metabolic interventions and outcomes in ASD: special diets
Many of our families and caregivers are interested in dietary interventions for ASD. While some diets are easy to implement and unlikely to cause harm, many of the diets require significant food restrictions. Moreover, they may provide additional stress and expense to the family and the person with ASD to maintain with little or no documented benefit on autistic symptoms or behaviors. We review several popular diets here (summarized in Table 1 ); however, caution should be taken with any new dietary intervention to avoid creating nutritional deficiencies or unnecessary stress for the person with ASD and their caregivers. Moreover, it is important to emphasize with families that systematic reviews of the literature have not found sufficient evidence to recommend any special diet for ASD .
Gluten-free, casein-free diets
Perhaps the most popular diet in people with ASD is the gluten-free, casein-free diet, often abbreviated as the GFCF diet. This diet can be quite restrictive as it removes most wheat and dairy products (with the exception of milk from some exotic animals that do not have casein, e.g., camel milk). In studies looking at nutrition in ASD, researchers found that 18% of people with ASD were already on gluten-free and/or casein-free diets (Hyman et al., 2012) . Gluten-free diets have gained popularity due a possible higher incidence of anti-gliadin antibodies in ASD. However, closer examination of a study comparing IgG antibodies in 37 children with ASD, 27 healthy siblings and 76 unrelated persons without ASD reveals no significant difference in anti-gliadin antibodies between the children with ASD and their neurotypical siblings (Lau et al., 2013) . The higher incidence was only found when comparing the children with ASD, all from the US, with the unrelated controls who were mostly from Sweden (62 out of 76). Moreover, there was no association with the increased anti-gliadin antibody and specific markers for celiac disease. The authors also stress that elevated IgG, with no concomitant increase in IgA, may not be related to gluten or even come from the gut (Lau et al., 2013) . Thus, at this time, there is no reliable test for gluten sensitivity in the absence of celiac disease (Buie, 2013) .
Multiple small studies have attempted to address whether there is a benefit for gluten-free, casein-free diets in people with ASD with mixed results. One of the best-controlled studies (Hyman et al., 2016) started the GFCF diet for 4-6 weeks in 3-to 5-year-olds under the guidance and monitoring of a dietician. Over the following 12 weeks, the children with ASD were given dietary challenges with food that contained gluten or casein with the parents and ABA-trained therapist, blind to the nature of the challenge, scoring any change in behavior. There was no association between the gluten or casein challenges and behavior. Nor was there an overall behavioral benefit of the diet (Hyman et al., 2016) . Other small randomized-control trials showed improvements on parentrated scales only (Knivsberg et al., 2002; Whiteley et al., 2010) ; however, these studies lacked monitoring of diet adherence or concurrent ASD treatments and interventions. In a small double-blinded study, where the food was provided to the families to better control dietary intake and compliance and the parents were blind to the treatment, no improvement in ASD symptoms were observed (Elder et al., 2006) .
Thus, when discussing gluten-free, casein-free diets with families and caregivers, clinicians should caution the parents, as evidence of the diet's efficacy in ASD is lacking. The diet also carries the risk of deficiencies in B vitamins, calcium, and vitamin D due to the restrictions on wheat and dairy products. For caregivers considering restriction diets for people with ASD, consultation with a dietician can be beneficial to insure good nutrition (Buie et al., 2010) . Although supplementation with vitamins is common in children on gluten-free, casein-free diets, vitamins are better absorbed from food than pills. Many children with or without ASD still have significant deficiencies, particularly in calcium and vitamin D, despite supplementation .
Ketogenic diets for ASD (in the absence of epilepsy)
Ketogenic diets are high-fat, low-carbohydrate diets that have been highly successful at treating some forms of epilepsy. They require strict adherence and, for epilepsy patients, are often monitored by specialized dieticians. There has also been interest in whether ketogenic diets may be useful for improving symptoms in ASD. Limited small trials (6-18 children) have suggested mild improvement in behavior and cognition symptoms for the children with ASD who were able to adhere to the diet (Cheng et al., 2017) . This diet is particularly difficult to implement in ASD, due to the many feeding issues discussed, and, notably, less than 38% of study participants were able to comply with the diet (Spilioti et al., 2013) . Moreover, it is not clear how long a person with ASD would be able to stay on the ketogenic diet without the known cardiovascular risks of a high-fat diet in addition to the likely changes in the microbiome (Shaffer et al., 2017) . Without further elucidation of the risks and potential benefits, we would not recommend a ketogenic diet for people with ASD, except where appropriate for the treatment of epilepsy.
Supplements
In absence of effective medications for treating the core symptoms of ASD, many families and caregivers have turned to nutritional supplements. We discuss some of the most popular supplements among our patients (summarized in Table 1 ). While some supplements may be quite benign, it is important to remind families and caregivers that the supplement industry is not regulated in the same way as prescription medications (Dodge, 2016) . Thus, there may not be scientific evidence to support the maker's claims regarding the health benefits, sufficient investigation and/or reporting of side effects, nor tight regulation over the precise amount of the active ingredient in the nutritional supplement (Marcus, 2016; Pawar and Grundel, 2017) . Thus, the dose can vary widely between batches, even in supplements from the same manufacturer (Dodge, 2016) . Moreover, many nutritional supplements are metabolized by same liver enzymes as many prescription medications, particularly antiepileptic or antianxiety medications, and thus may affect the efficacy (and/or toxicity) of concurrent drugs (Asher et al., 2017) . Caregivers should be encouraged to report all nutritional supplements to any prescribing physicians and their pharmacist to avoid harmful drug-supplement interactions.
Vitamins
Recent studies on nutrition in ASD found that 56%-66% of children with ASD surveyed were receiving vitamin supplements, compared to 31-37% of the general pediatric population (Hyman et al., 2012; Stewart et al., 2015) . The most common micronutrient deficiencies were in vitamins D, B6, calcium, potassium and choline-similar to neurotypical children-and were not corrected by taking vitamin supplements . Adolescent boys with ASD showed lower protein and calcium intake, which corresponded with lower bone mineral density scores (Neumeyer et al., 2018b) . There was also notably evidence of excess supplementation of vitamin A, folate, zinc, and copper in children with ASD. Thus, it would be prudent to test for vitamin deficiencies, when possible, before recommending supplements.
When specific vitamin deficiencies are identified, discussion with a dietician regarding dietary changes may be more effective and reduce the risk of excess supplementation. Studies have examined the effect of supplementation with vitamin D, B6, B12, magnesium, and/or folic acid with mixed results . Vitamin D supplementation, when successful at increasing vitamin D levels appeared to improve symptoms according to one meta-analysis . However, vitamin D deficiency is common in the general population as well who also report benefits from supplementation; hence, the benefits seen are unlikely to be specific to ASD (Hyman, 2012) .
Folinic acid
Studies are also underway to examine the efficacy of folinic acid, a reduced form of folate (vitamin B9) that is easier for the body to absorb and can cross the blood-brain barrier . High-dose folinic acid improves neurologic symptoms in cerebral folate deficiency, a disorder characterized by neurodevelopmental regression and diagnosed by low folate in cerebrospinal fluid. Autoantibodies to the folic acid receptor alpha have been identified in some people with ASD (Ramaekers et al., 2005) , and an open label study by the same authors found that high-dose folinic acid improved communication and repetitive behaviors (Frye et al., 2013) . A small double-blinded placebo control study was then performed (with 21 children in the treatment and 25 in the placebo group) that also showed improvement in language and other behavioral scoring scales for ASD, particularly for the cohort with folic acid receptor alpha autoantibodies . A larger, multi-center randomized control study of folinic acid (leucovorin) versus placebo is now planned (NCT02839915). It will be particularly interesting to see whether this treatment, which has few known side effects, has efficacy for people in ASD in general, or whether it may be useful for only a subpopulation with documented folate deficiency and autoantibodies.
Probiotics
Many families and caregivers are interested in whether probiotics may improve gastrointestinal (GI) symptoms, or even behavior and other cognitive symptoms, in ASD due to gut-brain interactions . In particular, recent studies have suggested increased gut permeability as a source for GI, and potentially cognitive, problems in ASD. Caution should be used, however, when interpreting these studies. For example, while zonulin, a biomarker for gut permeability, may be elevated in some people with ASD, another biomarker, sugar probes, was not elevated; this suggests that the elevated zonulin could be an epiphenomenon rather than part of the pathogenesis of ASD (Fasano and Hill, 2017) . While a benefit of probiotics on the core symptoms of ASD has not been established, they may improve GI symptoms , in particular, by decreasing constipation and abdominal pain in ASD (Fasano and Hill, 2017) .
N-acetylcysteine
N-acetylcysteine is a prodrug of the amino acid cysteine and a precursor to glutathione, which is involved in oxidative stress and scavenging free radicals. It is currently under investigation for use in multiple psychiatric disorders including depression, obsessive-compulsive disorder, bipolar depression and schizophrenia (Dean et al., 2011) . Comparison of N-acetylcysteine in children with ASD with and without concurrent treatment with the antipsychotic risperidone reported mild improvement in irritability but no improvement in repetitive behaviors (Ghanizadeh and Moghimi-Sarani, 2013) . Another small randomized control pilot with oral N-acetylcysteine in children with ASD found improvement in irritability and improved repetitive behaviors (Hardan et al., 2012) ; however, other studies failed to show benefit (Williamson et al., 2017) . Thus, further evidence of efficacy would be required before recommending this supplement to people with ASD and their caregivers.
Omega-3 fatty acids
Omega-3 fatty acids supplementation has been tested in large populations for improving cardiovascular health and cognitive function in aging (Derbyshire, 2018; Jia et al., 2019) . Due to the proposed antiinflammatory effects, there has also been interest whether additional omega-3 fatty acids could improve symptoms in ASD as well . A meta-analysis of 6 randomized control studies in people with ASD showed no benefit in 5 out of 6 of the trials, all limited by sample size Williamson et al., 2017) . As new refinements of the formulation become available, larger trials may be justified to see if any ASD-specific benefits can be seen from treatment, in addition to the possible overall health benefits.
New treatment targets?
A number of new metabolic interventions are in the pipeline as possible treatments for the core symptoms of ASD. Sulforaphane, a plant derivative, is thought to interact with heat shock proteins in the body imitating the metabolic effects of a fever . In a small study of teenagers with ASD, in which the parents had previously observed a subjective improvement in ASD symptoms when the teens had a fever, improvement in ASD symptoms was reported with the drug versus placebo; however, the placebo effect was much lower than expected . Another small study compared a single dose of intravenous suramin, an antipurinergic therapy targeting mitochondrial function, in 5 boys with ASD to saline infusion alone in 5 boys with ASD (Naviaux et al., 2017) . Mild improvement was seen on subjective outcomes, and two previously non-verbal children spoke their first sentences. However, further investigation will be necessary to test efficacy. There is also increasing interest in using cannabidiol, an anxiolytic component from the cannabis plant, to treat behavioral problems in ASD (Aran et al., 2019) . A whole plant extract containing a 20:1 ratio of cannabidiol (CBD) to tetrahydrocannabinol (THC) was given to 60 children with ASD, the majority of whom were also being treated with antipsychotics or other psychiatric medications for severe behavioral problems (Aran et al., 2019) . While the study reported subjective improvement in behavioral problems in 61% of the children, half of the cohort had to be switched to up to a 6:1 ratio of CBD:THC due to insufficient response and 27% of the children stopped the trial earlier due to poor tolerance. The most common side effects were hypervigilance, sleep disturbances, irritability, and loss of appetite. One child on the higher THC concentration had a psychotic episode. Current clinical trials are now underway to test CBD compounds in placebo-controlled cohorts of 100-150 children with ASD (Aran et al., 2019) .
Conclusions and future directions
Further research is necessary to test metabolic and nutritional interventions for efficacy in treating the core symptoms of ASD. Attention by medical and non-medical providers to nutritional status and possible comorbid symptoms, due to poor diet or gastrointestinal distress, in children and adults with ASD can result in profound improvement in ASD-related symptoms, particularly self-injurious or aggressive behaviors, and overall health. Indeed, encouraging measures to improve overall health offer potential for increasing level of functioning and quality of life. When discussing possible metabolic or dietary interventions with families and caregivers, however, it is important to emphasize that there are currently no evidence-based recommendations for metabolic treatments for people with ASD.
